Overview

A Study of Multiple Doses of Vesnarinone in Advanced HIV Disease

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To evaluate the safety and tolerability of four doses of oral vesnarinone in patients with advanced HIV disease.
Phase:
Phase 1
Details
Lead Sponsor:
Otsuka America Pharmaceutical
Treatments:
Vesnarinone